BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 19409033)

  • 1. Glioblastoma multiforme: a review of therapeutic targets.
    Kanu OO; Mehta A; Di C; Lin N; Bortoff K; Bigner DD; Yan H; Adamson DC
    Expert Opin Ther Targets; 2009 Jun; 13(6):701-18. PubMed ID: 19409033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma multiforme: a review of where we have been and where we are going.
    Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic targets and agents for glioblastoma migrating cells.
    Di C; Mattox AK; Harward S; Adamson C
    Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
    Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
    Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
    Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.
    Kamiryo T; Tada K; Shiraishi S; Shinojima N; Kochi M; Ushio Y
    Neurosurgery; 2004 Feb; 54(2):349-57; discussion 357. PubMed ID: 14744281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme.
    Nunna RS; Khalid SI; Patel S; Sethi A; Behbahani M; Mehta AI; Adogwa O; Byrne RW
    World Neurosurg; 2021 May; 149():e1026-e1037. PubMed ID: 33482415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
    De Carlo E; Gerratana L; De Maglio G; Buoro V; Cortiula F; Gurrieri L; Isola M; Fasola G; Puglisi F; Pizzolitto S; Rizzato S
    J Neurooncol; 2018 Dec; 140(3):559-568. PubMed ID: 30132165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult Glioblastoma.
    Alexander BM; Cloughesy TF
    J Clin Oncol; 2017 Jul; 35(21):2402-2409. PubMed ID: 28640706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatment strategies for glioblastoma multiforme.
    Carlsson SK; Brothers SP; Wahlestedt C
    EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
    Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
    Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.